De toelichting op onze huidige investeringen in momenteel alleen in het Engels beschikbaar.
Azelis is the world's second-largest distributor of specialty chemicals, connecting 2,800 suppliers with over 60,000 customers across various industries. Founded in 2001 and listed on the Belgian stock exchange in 2021, it serves as a key link between large chemical manufacturers and smaller customers that are costly for producers to reach directly.
Specialty chemicals, though used in small amounts, are essential for enhancing product performance, texture, and compliance. As demand for customized solutions grows, Azelis plays a key role in supplying these complex, high-value chemicals to a fragmented market.
Azelis is more than a distributor—it’s a strategic partner in product development, regulatory compliance, and supply chain efficiency. With 70+ innovation labs, it collaborates closely with clients to create customized solutions. For example, Azelis worked with a personal care brand to develop a sulfate-free, moisturizing shampoo. By sourcing gentle surfactants, natural oils, and conditioning agents from multiple suppliers, it formulated a product that met both the client’s performance and sustainability requirements while ensuring regulatory compliance.
Its scale, expertise, and strong relationships make it a one-stop shop for customers needing complex product formulations. As orders become more intricate, Azelis’ role grows even more valuable. Its vast network attracts both suppliers and customers, reinforcing its competitive edge in a market shaped by outsourcing, regulation, and demand for innovation.
Azelis is a resilient business with steady recurring revenue, exclusive supplier deals, and a flexible, asset-light model. Its specialty chemicals are essential in customer formulations, leading to long-term repeat business.
During COVID-19, Azelis proved its strength by maintaining stable revenues and growing earnings, as its chemicals are critical in recession-resistant sectors like pharmaceuticals, personal care, and food. With 62% of revenue from life sciences, strong supplier partnerships, and a flexible cost structure, Azelis is well-positioned to thrive even during economic downturns.
Azelis’ leadership team is experienced, stable, and well-aligned with shareholders. CEO Anna Bertona has been with the company for over a decade, previously leading the European division, while CFO Thijs Bakker has played a key role in Azelis' financial growth since 2016.
Management has a strong track record of exceeding expectations. Since the IPO, they guided for 8-10% revenue growth but delivered 23%, and their margin improvements have far outpaced forecasts.
With insiders owning 5.6% of the company through the AKITA management vehicle, leadership has real skin in the game, ensuring a strong focus on long-term success.
Azelis has strong pricing power because its specialty chemicals are essential to customer formulations and difficult to replace. Though used in small amounts, they significantly enhance product performance, ensuring steady demand.
The industry’s complex and opaque pricing structure allows Azelis to pass on cost increases with ease. Exclusive supplier agreements further reinforce this advantage—once a chemical is embedded in production, switching becomes nearly impossible.
High barriers to entry also work in Azelis’ favor. Its exclusive supplier relationships, regulatory expertise, and scale make it difficult for new players to compete. Customers depend on Azelis’ R&D support, making transitions costly and disruptive. With high retention rates and deep industry integration, Azelis remains a dominant force in specialty chemicals distribution.
Azelis has achieved strong growth since 2018, with both revenue and EBITA increasing significantly at annual rates of 17% and 28%. This growth has resulted in improved profitability, with EBITA margins rising from 7% to 11%. This improvement is largely attributed to Azelis’ scalable, asset-light business model, which allows for efficient growth without the need for heavy investments in physical assets.
The specialty chemicals market is evolving, driven by factors such as increasing product complexity, greater outsourcing, stricter regulations, and industry consolidation. Azelis is well-positioned to capitalize on these shifts, operating in a fragmented market where the top 10 players control just 13%. The company benefits from making a dozen or so strategic acquisitions annually, which provide additional growth opportunities as outsourcing continues to rise. Azelis’ strong product offerings, technical expertise, and digital capabilities further differentiate it from smaller competitors.
Looking ahead, Azelis is expected to continue growing both revenue and EBITA margins, driven by organic expansion, strategic acquisitions, and favorable market trends—especially in fast-growing regions like Asia. As the company scales, profitability should continue to improve, supporting its long-term growth potential. With its strong position in an expanding market, Azelis represents an attractive investment opportunity for the future.
Azelis’ commitment to innovation extends to its ESG strategy, using its technical expertise and labs to create sustainable formulations for customers. For example, in the Home Care & Industrial Cleaning segment, Azelis reformulated a laundry detergent to reduce surfactants by 20%, addressing environmental concerns without compromising effectiveness.
Despite the chemical industry's ESG risks, such as water use and chemical waste, Azelis actively manages these challenges. The company adheres to Responsible Care® and Responsible Distribution® programs, and since 2020, it has been a member of Together for Sustainability (TfS), ensuring its supply chain meets global ESG standards. As of 2024, 84% of Azelis' revenue comes from ESG-assessed suppliers.
We invested in Azelis for its strong growth, attractive valuation, and solid market position. Since its 2021 IPO, Azelis has nearly doubled operating income, but macroeconomic concerns and an equity overhang have pressured the stock, creating an entry point at 11x forward EBITA—30% below peer IMCD and its historical average. As the overhang resolves, we expect the valuation gap to narrow.
Azelis is well-positioned to benefit from trends like continued outsourcing, tighter regulations, and consolidation. With strong M&A execution, operational leverage, and market share growth, it’s poised for 10% annual revenue growth and expanding EBITA margin. This positions Azelis for mid-teens annual earnings growth.
Given the company’s strong fundamentals, scalable model, and favourable industry tailwinds, we are confident in its potential to deliver substantial shareholder returns in the years ahead.
Participaties in het Fund zijn gekwalificeerd voor verkoop in Nederland. SilverCross Global Small-Cap Fund houdt zich momenteel nog niet bezig met proactieve marketing richting beleggers buiten Nederland.
De minimum investering bedraagt EUR 100.000. Elke vervolg investering bedraagt minimaal EUR 25.000.
Voordat u een beslissing neemt om te investeren in SilverCross Global Small-Cap Fund, adviseren wij u het Prospectus te lezen.
SilverCross Global Small-Cap Fund wordt gedistribueerd via IBS Asset Management BV en via vergunning houdende financiële instellingen in de EU/EVA. Beleggers die wensen te investeren via hun eigen adviseur kunnen dit doen middels het doorgeven van de ISIN code: NL0010832242.
Alle inkomen die het Fund verkrijgt is fiscaal transparant. Dat betekent dat inkomen zoals dividend en rente wordt belast op basis van uw persoonlijke fiscale situatie. Wij adviseren uw belastingadviseur te raadplegen over de mogelijke belastingconsequenties van een investering in SilverCross Global Small-Cap Fund. Op verzoek is een opsomming van het inkomen van het Fund beschikbaar ten behoeve van uw belastingaangifte.
Beleggers wiens vermogen in ‘Box 3’ wordt belast, dienen de netto vermogenswaarde van hun investering in het Fund op 1 januari van elk kalenderjaar te melden op hun belastingaangifte, zonder enige verdere informatie te hoeven verschaffen met betrekking tot inkomen dat het Fund heeft gegenereerd.
Uw inschrijving zal worden verwerkt op de eerste Transactiedatum volgend na ontvangst van uw investeringsbedrag. Uitgifte en inname van participaties vindt wekelijks plaats op woensdag, of de eerste handelsdag daarna als Euronext Amsterdam gesloten is.
SilverCross Global Small-Cap Fund heeft een ‘open-end’ structuur. Participaties worden uitgegeven of ingenomen tegen de netto vermogenswaarde (NAV) per participatie plus of minus een anti-verwateringsheffing van 0.3%. Deze heffing wordt gerekend om transactiekosten als gevolg van in- en outflows in het Fund te dekken. De heffingsopbrengst komt volledig ten goede aan het Fund. Voor meer informatie over de anti-verwateringsheffing, zie het Prospectus.
De Beheerder wijst potentiële investeerders erop dat een investering in het Fund moet worden gezien als een lange termijn belegging. Daarom heeft het Fund, in geval een investeerder haar participaties wenst te verkopen binnen 90 dagen na zijn of haar laatste aankoop, een anti-verwateringsheffing van 3.0% van de netto vermogenswaarde per participatie ten laste van de opbrengst. Deze maatregel is bedoeld om regelmatig handelen in de participaties van het Fund te ontmoedigen.
Het is de Beheerder toegestaan om inschrijvingen of onttrekkingen te limiteren in het belang van bestaande investeerders. Voor meer informatie over situaties waarin dit zou kunnen voorkomen, wordt verwezen naar het Prospectus.